Christelle MAZUET

Dr. Christelle MAZUET

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2017 in Toxins
Verified
Journal Article
Open access
PDF file
MPMichael Peck
Michael Peck
TSTheresa J. Smith
Theresa J. Smith
FAFabrizio Anniballi
Fabrizio Anniballi
JAJohn Austin
John Austin
LBLuca Bano
Luca Bano
SSSandra C. Stringer
Sandra C. Stringer
Botulinum neurotoxins are diverse proteins. They are currently represented by at least seven serotypes and more than 40 subtypes. New clostridial strains that produce novel neurotoxin variants are being identified with increasing frequency, which presents challenges when organizing the nomenclature surrounding these neurotoxins. Worldwide, researchers are faced with the possibility that toxins having identical sequences may be given different designations or novel toxins having unique sequences may be given the same designations on publication. In order to minimize these problems, an ad hoc committee consisting of over 20 researchers in the field of botulinum neurotoxin research was convened to discuss the clarification of the issues involved in botulinum neurotoxin nomenclature. This publication presents a historical overview of the issues and provides guidelines for botulinum neurotoxin subtype nomenclature in the future.

9 July 2009 in Journal of Applied Microbiology
Verified
Journal Article
Open access
PDF file
PFP. Fach
P. Fach
PMP. Micheau
P. Micheau
CMChristelle MAZUET
Christelle MAZUET
SPS. Perelle
S. Perelle
MPM. Popoff
M. Popoff
Aims: To develop real-time PCR assays for tracking and tracing clostridia responsible for human botulism. Methods and Results: Real-time PCR assays based on the detection of the genes ntnh encoding the nontoxin-nonhaemagglutinin (NTNH) proteins or the most homologous regions of the botulinum neurotoxin (bont) genes have been developed together with four real-time PCR assays, each being specific of the genes bont/A, bont/B, bont/E, bont/F and enables a toxin type-specific identification. The specificity of the assays was demonstrated using a panel of botulinum toxin producing clostridia (29 strains), nonbotulinum toxin producing clostridia (21 strains) and various other bacterial strains. The toxin type-specific assays had a sensitivity of 100 fg–1000 fg of total DNA in the PCR tube (25–250 genome equivalents) which correspond to 103 to 104 cells ml−1. After a 48 h enrichment in anaerobic conditions, these PCR assays allowed the detection of Clostridium botulinum type A in a naturally contaminated sample of ‘foie gras’ suspected in a C. botulinum outbreak. Conclusion: These PCR tests are specific and reliable for detection of heterogeneous BoNT producing clostridia responsible for human botulism. Significance and Impact of the Study: Adoption of these PCR assays is a step forward a reliable and rapid detection of these clostridia in food samples.

1 March 2007 in The American Journal of Pathology
Verified
Journal Article
Closed access
BGBlandine Geny
Blandine Geny
HKHuot Khun
Huot Khun
CFCatherine Fitting
Catherine Fitting
LZLeticia Zarantonelli
Leticia Zarantonelli
CMChristelle MAZUET
Christelle MAZUET
MPMichel R. Popoff
Michel R. Popoff

1 February 1996 in Cytokine
Verified
Journal Article
Closed access
CMChristelle MAZUET
Christelle MAZUET
CPChristina Pitton
Christina Pitton
CFCatherine Fitting
Catherine Fitting
JCJean- Marc Cavaillon
Jean- Marc Cavaillon

26 August 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CMChristelle MAZUET
Christelle MAZUET
JDJulie Dano
Julie Dano
MPMichel R. Popoff
Michel R. Popoff
CCChristophe Créminon
Christophe Créminon
HVHerve Volland
Herve Volland
Botulinum toxins, i.e. BoNT/A to/G, include the most toxic substances known. Since botulism is a potentially fatal neuroparalytic disease with possible use as a biowarfare weapon (Centers for Disease Control and Prevention category A bioterrorism agent), intensive efforts are being made to develop vaccines or neutralizing antibodies. The use of active fragments from non-human immunoglobulins (F(ab')2, Fab', scFv), chemically modified or not, may avoid side effects, but also largely modify the in vivo half-life and effectiveness of these reagents. We evaluated the neutralizing activity of several monoclonal anti-BoNT/A antibodies (mAbs). F(ab')2 fragments, native or treated with polyethyleneglycol (PEG), were prepared from selected mAbs to determine their half-life and neutralizing activity as compared with the initial mAbs. We compared the protective efficiency of the different biochemical forms of anti-toxin mAbs providing the same neutralizing activity. Among fourteen tested mAbs, twelve exhibited neutralizing activity. Fragments from two of the best mAbs (TA12 and TA17), recognizing different epitopes, were produced. These two mAbs neutralized the A1 subtype of the toxin more efficiently than the A2 or A3 subtypes. Since mAb TA12 and its fragments both exhibited the greatest neutralizing activity, they were further evaluated in the therapeutic experiments. These showed that, in a mouse model, a 2- to 4-h interval between toxin and antitoxin injection allows the treatment to remain effective, but also suggested an absence of correlation between the half-life of the antitoxins and the length of time before treatment after botulinum toxin A contamination. These experiments demonstrate that PEG treatment has a strong impact on the half-life of the fragments, without affecting the effectiveness of neutralization, which was maintained after preparation of the fragments. These reagents may be useful for rapid treatment after botulinum toxin A contamination.

29 April 2016 in Genome Biology and Evolution
Verified
Journal Article
Open access
CMChristelle MAZUET
Christelle MAZUET
CLChristine Legeay
Christine Legeay
JSJean Sautereau
Jean Sautereau
LMLaurence Ma
Laurence Ma
CBChristiane Bouchier
Christiane Bouchier
Michel PopoffMichel Popoff
Michel Popoff
In France, human botulism is mainly food-borne intoxication, whereas infant botulism is rare. A total of 99 group I and II Clostridium botulinum strains including 59 type A (12 historical isolates [1947-1961], 43 from France [1986-2013], 3 from other countries, and 1 collection strain), 31 type B (3 historical, 23 recent isolates, 4 from other countries, and 1 collection strain), and 9 type E (5 historical, 3 isolates, and 1 collection strain) were investigated by botulinum locus gene sequencing and multilocus sequence typing analysis. Historical C. botulinum A strains mainly belonged to subtype A1 and sequence type (ST) 1, whereas recent strains exhibited a wide genetic diversity: subtype A1 in orfX or ha locus, A1(B), A1(F), A2, A2b2, A5(B2') A5(B3'), as well as the recently identified A7 and A8 subtypes, and were distributed into 25 STs. Clostridium botulinum A1(B) was the most frequent subtype from food-borne botulism and food. Group I C. botulinum type B in France were mainly subtype B2 (14 out of 20 historical and recent strains) and were divided into 19 STs. Food-borne botulism resulting from ham consumption during the recent period was due to group II C. botulinum B4. Type E botulism is rare in France, 5 historical and 1 recent strains were subtype E3. A subtype E12 was recently identified from an unusual ham contamination. Clostridium botulinum strains from human botulism in France showed a wide genetic diversity and seems to result not from a single evolutionary lineage but from multiple and independent genetic rearrangements.